BRIEF published on 10/26/2026 at 07:10, 15 days 12 hours ago TME Pharma Extends Debt Maturity to Enhance Financial Visibility Shareholder Value Debt Maturity Financial Stability Bond Financing NOX-A12 Licensing
PRESS RELEASE published on 10/26/2026 at 07:05, 15 days 12 hours ago TME Pharma extends financial visibility by lengthening debt maturity to June 2028
BRIEF published on 09/16/2026 at 08:05, 1 month 24 days ago TME Pharma NV's strategy and financial commitment Biotechnology Partnerships Financial Strategy TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 1 month 24 days ago TME PHARMA CEO MESSAGE TME Pharma CEO message emphasizes strategic approach, financial discipline, and long-term value creation for shareholders. Updates on NOX-A12, cost-reduction strategy, and future plans CEO Message Financial Discipline TME Pharma Strategic Approach NOX-A12
BRIEF published on 08/24/2026 at 08:10, 2 months 17 days ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
PRESS RELEASE published on 08/24/2026 at 08:05, 2 months 17 days ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
BRIEF published on 10/30/2025 at 21:05, 1 year ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 1 year ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 1 year 2 months ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 1 year 2 months ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
Published on 11/10/2026 at 14:45, 5 hours 5 minutes ago An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 5 hours 19 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 5 hours 20 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 5 hours 20 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 14:00, 5 hours 50 minutes ago Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Published on 11/10/2026 at 18:54, 55 minutes ago REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 1 hour 4 minutes ago Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Published on 11/10/2026 at 18:30, 1 hour 20 minutes ago Shelly Group Accelerates Revenue Growth in the Third Quarter and Confirms Full-Year 2026 Guidance
Published on 11/10/2026 at 18:20, 1 hour 29 minutes ago Edison issues report on Custodian Property Income REIT (LSE: CREI)
Published on 11/10/2026 at 17:31, 2 hours 18 minutes ago CNP Assurances SA announces the success of the issuance of a €500 million Tier 2 subordinated bond.
Published on 11/10/2026 at 14:00, 5 hours 49 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 2 to November 6, 2026
Published on 11/10/2026 at 11:02, 8 hours 47 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Published on 11/10/2026 at 07:00, 12 hours 50 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/09/2026 at 18:30, 1 day 1 hour ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
